Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

GBI Research
141 Pages - GBI10608
$9,990.00

Dermatology is a highly diverse therapy area, in terms of severity and clinical presentation, which deals with diseases of the skin, hair and nails. Whilst an orphan disease is a disease that is neglected in terms of research and funding and in the US, a disease is considered to be rare if it affects fewer than 200,000 people.

Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. In particular, disease visibility can have a profoundly negative impact on patient confidence. However, the current therapeutics market is a highly genericized therapy area and there exists a significant unmet need for more efficacious and safer treatment options that treat the underlying causes of disease as opposed to managing the symptoms.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key diseases, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus, as these conditions have the largest pipelines within the therapy area.

The premium product market size for orphan and rare dermatology therapeutics was valued at $1.64 billion in 2017 and it is expected to grow at a compound annual growth rate (CAGR) of 20.5% to $6.07 billion in 2024.

Scope

The orphan and rare dermatology market landscape is expected to change and grow. Novel targets are expected to enter the market and drive market growth with a move towards disease modifying drugs instead of drugs which manage symptoms.
Overall, there are 262 orphan and rare dermatology products in the pipeline.
Which molecular targets are most prominent within the pipeline?
How do the key indications differ in terms of molecule type?
How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action are most common for pipeline drugs?
The premium products market size for orphan and rare dermatology therapeutics is expected to grow, from $1.64 billion in 2017 to $6.07 billion in 2024, at a CAGR of 20.5%.
Which products will contribute to market growth most, and will any achieve blockbuster status?
Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the orphan and rare dermatology market set to change?
What CAGR will these companies register in the forecast period?
How many strategic consolidations have been completed in the past decade?
Which types of assets attract the largest deal values?
Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the six key indications.
Visualize the composition of the orphan and rare dermatology market overall and across each key indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
Identify trends and developments, in terms of molecule type and molecular target, within the overall orphan and rare dermatology pipeline, as well as for each of the six key indications.
Understand the growth in patient epidemiology and market revenues for the orphan and rare dermatology market globally, and across the key players and product types.
Consider market opportunities and potential risks by examining the incentives and challenges of drug development within the orphan market space and the trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, molecule type and molecular target.
Recognize how the evolving treatment landscape will drive market growth to 2024 and understand the contributions that different products, molecular targets and companies will make to this growth.
Identify commercial opportunities in the orphan and rare dermatology deals landscape by analyzing trends in licensing and co-development deals.

'

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Overview
2.1.1 Overview of the Dermatology Market
2.1.2 Overview of Orphan and Rare Diseases
2.1.3 Overview of Orphan and Rare Dermatological Diseases
2.2 Symptoms
2.3 Diagnosis
2.3.1 Systemic Sclerosis
2.3.2 Alopecia
2.3.3 Epidermolysis Bullosa
2.3.4 Pemphigus Vulgaris
2.3.5 Vitiligo
2.3.6 Cutaneous Lupus Erythematosus
2.4 Etiology
2.5 Pathophysiology
2.5.1 Systemic sclerosis
2.5.2 Alopecia
2.5.3 Epidermolysis Bullosa
2.5.4 Pemphigus Vulgaris
2.5.5 Vitiligo
2.5.6 Cutaneous Lupus Erythematosus
2.6 Epidemiology
2.6.1 Systemic sclerosis
2.6.2 Alopecia
2.6.3 Epidermolysis Bullosa
2.6.4 Pemphigus Vulgaris
2.6.5 Vitiligo
2.6.6 Cutaneous Lupus Erythematosus
2.7 Co-morbidities and Complications
2.7.1 Systemic sclerosis
2.7.2 Alopecia
2.7.3 Epidermolysis Bullosa
2.7.4 Pemphigus Vulgaris
2.7.5 Vitiligo
2.7.6 Cutaneous Lupus Erythematosus
2.8 Prognosis
2.8.1 Systemic Sclerosis
2.8.2 Alopecia
2.8.3 Epidermolysis Bullosa
2.8.4 Pemphigus Vulgaris
2.8.5 Vitiligo
2.8.6 Cutaneous Lupus Erythematosus
2.9 Treatment
2.9.1 Systemic Sclerosis
2.9.2 Alopecia
2.9.3 Epidermolysis Bullosa
2.9.4 Pemphigus Vulgaris
2.9.5 Vitiligo
2.9.6 Cutaneous Lupus Erythematosus
3 Key Marketed Products
3.1 Overview
3.2 Premium Drugs
3.2.1 Humira (adalimumab) - AbbVie
3.2.2 Ilaris (canakinumab) - Novartis
3.2.3 Afinitor (everolimus) - Novartis
3.2.4 Kineret (anakinra) - Swedish Orphan Biovitrum
3.2.5 Arcalyst (rilonacept) - Regeneron Pharmaceuticals
3.2.6 Tracleer (bosentan) - Johnson & Johnson
3.2.7 Thalomid (thalidomide) - Celgene
3.3 Highly Genericized Drugs
3.3.1 Medrol (methylprednisolone) - Pfizer
3.3.2 Meticorten/Rayos (Prednisone) - Merck & Co./Horizon Pharma
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type and Program Type
4.2.1 Overall Pipeline
4.2.2 Pipeline by Key Indication
4.3 Molecular Targets in the Pipeline
4.3.1 Overall Pipeline
4.3.2 Pipeline by Key Indication
4.4 Clinical Trials Landscape
4.4.1 Challenges Associated with Clinical Trials for Orphan and Rare Diseases
4.4.2 Incentives for Clinical Trials for Orphan and Rare Diseases
4.4.3 Clinical Trial Failure Rates
4.4.4 Clinical Trial Duration
4.4.5 Clinical Trial Size
4.4.6 Cumulative Clinical Trial Size
4.5 Assessment of Key Pipeline Products
4.5.1 Epidiolex (cannabidiol) - GW Pharmaceuticals
4.5.2 Episalvan (birch bark extract) - Amryt Pharma
4.5.3 KB-103 - Krystal Biotech
4.5.4 Givosiran - Alnylam Pharmaceuticals
4.5.5 EB-101 - Abeona Therapeutics
4.5.6 OTL-103 - Orchard Therapeutics
4.5.7 Siponimod - Novartis
4.5.8 FCX-007 - Fibrocell Science
5 Multi-scenario Market Forecast to 2024
5.1 Market Size
5.2 Revenue Forecast by Molecular Target
5.2.1 Products Acting on Interleukins
5.2.2 Products Acting on Tumor Necrosis Factor-Alpha
5.2.3 Products Acting on Tyrosine Protein Kinases
5.2.4 Products Acting on Hormones and Hormone Receptors
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Novartis
6.1.2 GW Pharmaceuticals
6.1.3 AbbVie
6.1.4 Roche
6.1.5 Pfizer
6.1.6 Amryt Pharma
6.1.7 GlaxoSmithKline
6.1.8 Celgene
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Key Indication and Value
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Key Indication and Value
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values
8 Appendix
8.1 References
8.2 Figures of All Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Orphan and Rare Dermatology Drugs Market, Global, Symptoms of the Key Indications, 2018
Table 2: Orphan and Rare Dermatology Drugs Market, Global, Etiology of the Key Indications, 2018
Table 3: Orphan and Rare Dermatology Drugs Market, Global, Prognosis for Epidermolysis Bullosa, 2018
Table 4: Orphan and Rare Dermatology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
Table 5: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Humira, 2018
Table 6: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Ilaris, 2018
Table 7: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Afinitor, 2018
Table 8: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Kineret, 2018
Table 9: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Arcalyst, 2018
Table 10: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Tracleer, 2018
Table 11: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Thalomid, 2018
Table 12: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Methylprednisolone, 2018
Table 13: Orphan and Rare Dermatology Drugs Market, Global, Approved Orphan and Rare Dermatology Indications for Meticorten, 2018
Table 14: Orphan and Rare Dermatology Drugs Market, US, Approved Orphan and Rare Dermatology Indications for Rayos, 2018
Table 15: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024
Table 16: Orphan and Rare Dermatology Drugs Market, Global, Forecast Revenue by Company (%), 2017-2024
1.2 List of Figures
Figure 1: Orphan and Rare Dermatology Drugs Market, 7MM, Epidemiology Patterns for Systemic Sclerosis (Scleroderma), 2017-2024
Figure 2: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Humira ($bn), 2006-2024
Figure 3: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Ilaris ($bn), 2009-2024
Figure 4: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Afinitor ($bn), 2008-2024
Figure 5: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Kineret ($m), 2008-2024
Figure 6: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Arcalyst ($m), 2008-2024
Figure 7: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Tracleer ($bn), 2006-2024
Figure 8: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Thalomid ($m), 2006-2024
Figure 9: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue for Medrol ($m), 2008-2024
Figure 10: Orphan and Rare Dermatology Drugs Market, US, Annual Revenue for Rayos ($bn), 2013-2024
Figure 11: Orphan and Rare Dermatology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 12: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 13: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
Figure 14: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018
Figure 15: Orphan and Rare Dermatology Drugs Market, Global, Overall Pipeline by Molecular Target and Stage of Development, 2018
Figure 16: Orphan and Rare Dermatology Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018
Figure 17: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2018
Figure 18: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
Figure 19: Orphan and Rare Dermatology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018
Figure 20: Orphan and Rare Dermatology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018
Figure 21: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Epidiolex ($m), 2019-2024
Figure 22: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Episalvan (birch bark extract) ($m), 2020-2024
Figure 23: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for KB-103 ($m), 2021-2024
Figure 24: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Givosiran ($m), 2019-2024
Figure 25: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for EB-101 ($m), 2020-2024
Figure 26: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for OTL-103 ($m), 2021-2024
Figure 27: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for Siponimod ($m), 2021-2024
Figure 28: Orphan and Rare Dermatology Drugs Market, Global, Revenue Forecast for FCX-007 ($m), 2021-2024
Figure 29: Orphan and Rare Dermatology Drugs Market, Global, Premium Product Market Size ($bn), 2017-2024
Figure 30: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins ($m), 2017-2024
Figure 31: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-α ($m), 2017-2024
Figure 32: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Tyrosine Protein Kinases ($m), 2019-2024
Figure 33: Orphan and Rare Dermatology Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Receptors ($m), 2017-2024
Figure 34: Orphan and Rare Dermatology Drugs Market, Global, Company Analysis Matrix, 2017-2024
Figure 35: Orphan and Rare Dermatology Drugs Market, Global, Cluster by CAGR and Market Share, 2017-2024
Figure 36: Orphan and Rare Dermatology Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024
Figure 37: Orphan and Rare Dermatology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024
Figure 38: Orphan and Rare Dermatology Drugs Market, Global, Revenues by Route of Acquisition, 2017-2024
Figure 39: Orphan and Rare Dermatology Drugs Market, Global, Novartis Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 40: Orphan and Rare Dermatology Drugs Market, Global, GW Pharmaceuticals Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 41: Orphan and Rare Dermatology Drugs Market, Global, AbbVie Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 42: Orphan Dermatology Drugs Market, Global, Roche Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2018-2024
Figure 43: Orphan and Rare Dermatology Drugs Market, Global, Pfizer Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 44: Orphan and Rare Dermatology Drugs Market, Global, Amryt Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 45: Orphan and Rare Dermatology Drugs Market, Global, GlaxoSmithKline Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2018-2024
Figure 46: Orphan and Rare Dermatology Drugs Market, Global, Celgene Orphan and Rare Dermatology Annual Revenue Forecast ($m), 2017-2024
Figure 47: Orphan and Rare Dermatology Drugs Market, Global, Late-Stage Pipeline Developers by Type, 2018
Figure 48: Orphan and Rare Dermatology Drugs Market, Global, Pipeline and Late-Stage Developers by Level of Orphan and Rare Dermatology Specialization, 2018
Figure 49: Orphan and Rare Dermatology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Orphan and Rare Dermatology, 2024
Figure 50: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006-2018
Figure 51: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Indication, 2006-2018
Figure 52: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006-2018
Figure 53: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2018
Figure 54: Orphan and Rare Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006-2018
Figure 55: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006-2018
Figure 56: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Key Indication, 2006-2018
Figure 57: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006-2018
Figure 58: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2018
Figure 59: Orphan and Rare Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006-2018
Figure 60: Orphan and Rare Dermatology Drugs Market, Global, All Pipeline Products, 2018 (part 1)

$9,990.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports